Even though CAR-T cells are found to be very effective for the treatment of CD19+B cell lymphomas and leukemia cells, it also destroys all the normal CD19+B cells in the patient body (115, 116). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.